Perrigo Company and Flamel Technologies have entered into an exclusive licensing agreement for LiquiTime® extended release suspension. The technology will be utilized in the development of a portfolio of extended release suspension products intended for the U.S. OTC marketplace.
Michael Anderson, CEO Flamel, "We are very pleased to partner with Perrigo on our LiquiTime® technology and look forward to continued successful development programs and commercial launches with Perrigo."
Perrigo's Chairman and CEO Joseph C. Papa stated, "This partnership with Flamel on their innovative LiquiTime® technology demonstrates our continued focus on the 'Base Plus Plus Plus' strategy. This is yet another excellent example of Perrigo's commitment to providing Quality Affordable Healthcare Products® for our customers across the globe."